Nuo Therapeutics, Inc 8-K, filed Oct 10, 2025
Nuo Therapeutics, Inc. (AURX)
8-K
2025-10-10
For: 2025-10-07
View Original
Added on
April 06, 2026
About this 8-K
Nuo Therapeutics, Inc filed this 8-K on October 10, 2025, reporting on events of October 7, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 5.08: Shareholder director nominations
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 7, 2025
(Exact name of Registrant as Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
|
of Incorporation)
|
File Number)
|
Identification No.)
|
(Address of Principal Executive Offices) (Zip Code)
(346 ) 396-4770
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act: None
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
|
|
Emerging growth company
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 7, 2025, the Board of Directors of Nuo Therapeutics, Inc. (the “Company”) and its Compensation, Nominating and Governance Committee (the “Committee”) approved an increase in the salaries of David E. Jorden, Chief Executive and Financial Officer of the Company, and Peter A. Clausen, Chief Scientific and Operating Officer of the Company. Effective as of October 1, 2025 (the beginning of fourth quarter of 2025), the salary of Mr. Jorden is $325,000 and the salary of Mr. Clausen is $290,000. In approving the salary increases, the Committee considered, among other factors, the improvement in the Company’s business and financial condition in 2025 compared to prior years.
Item 5.08 Shareholder Director Nominations.
To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
Item 8.01 Other Events.
On October 7, 2025, the Board of Directors of Nuo Therapeutics, Inc. (the “Company”) determined that the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”) will be held at the Company’s principal executive office at 8285 El Rio, Suite 190, Houston, Texas on December 16, 2025, or as otherwise set forth in the Company’s notice and proxy statement for the Annual Meeting to be filed no less than 40 days prior to the Annual Meeting.
Stockholders of the Company who wish to have a proposal, including nominations of persons for election to the Board of Directors, considered for inclusion in the Company’s proxy materials for the Annual Meeting must ensure that such proposal is received by, on or before the close of business on October 20, 2025, which date the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials, and which complies with the requirements of the Amended and Restated By-Laws of the Company (the “By-Laws”). To be eligible for inclusion in the proxy materials for the Annual Meeting, any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission and in the By-Laws. Proposals and notices must be in writing and received by the Company’s Secretary, David Jorden, addressed to: Nuo Therapeutics, Inc. Board of Directors, Attn: Secretary, 8285 El Rio, Suite 190, Houston, Texas 77054.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Nuo Therapeutics, Inc.
|
|||
|
By:
|
/s/ David E. Jorden
|
||
|
David E. Jorden
|
|||
|
Chief Executive and Chief Financial Officer
|
|||
| Date: October 10, 2025 | |||